ArticleCancer medicine2021
Incidence of gastrointestinal stromal tumor in Chinese urban population: A national population-based study.
Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Variation in worldwide incidence of Guillain-Barré syndrome: a population-based study in urban China and existing global evidence.Frontiers in immunology · 2024Pooled it
- [Current status and challenges of artificial intelligence and organoid technologies in precision diagnosis and treatment of gastrointestinal stromal tumors].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Review
- Application value of gastric contrast ultrasonography in gastric tumors.Insights into imaging · 2026Review
- Rare co-occurrence of gastrointestinal stromal tumors and leiomyomas: A case report and review of the literature.Experimental and therapeutic medicine · 2026Article
- A Large Gastrointestinal Stromal Tumor under the Disguise of a Gastric Diverticulum: Report of a Case and Review of the Literature.Surgical case reports · 2025Article
- Using body composition to predict treatment-related adverse events and disease-free survival in patients with gastrointestinal stromal tumors treated with imatinib: a retrospective cohort study.Frontiers in immunology · 2025Article
- An ultrasound based method for predicting the malignant potential of primary gastrointestinal stromal tumors preoperatively.Abdominal radiology (New York) · 2024Article
- Epidemiology and distribution of 207 rare diseases in China: A systematic literature review.Intractable & rare diseases research · 2024Review
- A radiomics-clinical combined nomogram-based on non-enhanced CT for discriminating the risk stratification in GISTs.Journal of cancer research and clinical oncology · 2023Article
- Fear of progression, loneliness, and hope in patients with gastrointestinal cancer: a cross-sectional relational study.Frontiers in psychology · 2023Article
- Laparoscopic subtotal gastrectomy in case of large subcardial GISTs.Journal of surgical case reports · 2022Article
- GIST and Ghrelin: To Be or Not to Be?Diagnostics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInformation on incidence of gastrointestinal stromal tumor (GIST), the most common type of mesenchymal tumor in gastrointestinal tract, was limited in China. This study aimed to estimate the incidence of GIST in urban population from mainland China in 2016.
methodsUrban Employee Basic Medical Insurance (UEBMI) and Urban Residence Basic Medical Insurance (URBMI) in China were used. The denominator of incidence was the total person-years of insured individuals in 2016 in the database, covering approximately 0.43 billion individuals. The numerator was the number of incident GIST cases in 2016.
resultsThe crude incidence in 2016 was 0.40 per 100,000 person-years (95% CI, 0.06-1.03). Male incidence was higher than female incidence (0.44 vs. 0.36, rate ratio: 1.22, p < 0.001). The mean age at diagnosis was 55.20 years (SD = 14.26) and the incidence among those aged 50 years or older was 2.63 times (0.84 vs. 0.32, p < 0.001) higher than those aged under 50. The highest incidence was observed in East China (2.29, 95% CI: 0.46-5.54).
conclusionsThe incidence of GIST in mainland China was lower than Europe, North America and Korea. The mean age at diagnosis of GIST in China was younger than that of Europe and Canada. This study provides useful information to further research, policy formulating and management of GIST.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.